Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data

References

• von Tresckow B, Engert A. Refractory hodgkin lymphoma. Curr Opin Oncol 2013;25:463-9
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin H, Bray F, et al. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Wordwide: IARC CancerBase No. 10. Available at: http://globocan.iarc.fr/ [Last accessed 2 September 2013]
   Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30
   PubMed Web of Science ®Google Scholar
• Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012;10:589-97
   PubMed Web of Science ®Google Scholar
• Borchmann P, Eichenauer DA, Engert A. State of the art in the treatment of Hodgkin lymphoma. Nat Rev Clin Oncol 2012;9:450-9
   PubMed Web of Science ®Google Scholar
• Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma. J Natl Compr Canc Netw 2011;9:1020-58
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Hodgkin Lymphoma. NCCN Clinical Practice Guidelines in Oncology 2014, Version 2. Available at: http://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf [Last accessed 4 March 2015]
   Google Scholar
• Villa D, Seshadri T, Puig N, et al. Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy. Haematologica 2012;97:751-7
   PubMed Web of Science ®Google Scholar
• Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006;354:1813-26
   PubMed Web of Science ®Google Scholar
• Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study – a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012;97:310-7
   PubMed Web of Science ®Google Scholar
• Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21:778-84
   PubMed Web of Science ®Google Scholar
• Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003;102:1458-65
   PubMed Web of Science ®Google Scholar
• Okeley NM, Miyamoto JB, Zhang X, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 2010;16:888-97
   PubMed Web of Science ®Google Scholar
• Wahl AF, Klussman K, Thompson JD, et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res 2002;62:3736-42
   PubMed Web of Science ®Google Scholar
• Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012;30:631-7
   PubMed Web of Science ®Google Scholar
• Seattle Genetics Inc. Adcetris® (brentuximab vedotin) for Injection. Prescribing Information, 2013. Available at: http://www.adcetris.com/pdf/ADCETRIS_Prescribing_Information.pdf [Last accessed 12 December 2013]
   Google Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;30:2183-9
   PubMed Web of Science ®Google Scholar
• Smith S, Chen R, Gopal A, et al. Long-term follow-up results of an ongoing pivotal study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma (HL). Haematologica 2012;97(Suppl 1):Abstract 1109
   Google Scholar
• Chen RW, Gopal AK, Smith SE, et al. Long-term survival analyses of an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts) 2012;120:Abstract 3689
   Google Scholar
• Gopal AK, Chen R, Smith SE, et al. Three-year follow-up data and characterization of long-term remissions from an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts) 2013;122:Abstract 4382
   Google Scholar
• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Choice of control group and related issues in clinical trials E10 (CPMP/ICH/364/96). Current Step 4 version, dated 20 July 2000. 2013. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E10/Step4/E10_Guideline.pdf [Last accessed 12 December 2013]
   Google Scholar
• Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 2002;20:221-30
   PubMed Web of Science ®Google Scholar
• Sureda A, Constans M, Iriondo A, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005;16:625-33
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88
   PubMed Web of Science ®Google Scholar
• Biggerstaff BJ, Tweedie RL. Incorporating variability in estimates of heterogeneity in the random effects model in meta-analysis. Stat Med 1997;16:753-68
   PubMed Web of Science ®Google Scholar
• Jackson D. The significance level of the standard test for a treatment effect in meta-analysis. Stat Biopharm Res 2009;1:92-100
   Web of Science ®Google Scholar
• Clopper C, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934;26:404-13
   Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86
   PubMed Web of Science ®Google Scholar
• Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007;25:2764-9
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007;18:1071-9
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Younes A, Carabasi MH, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2008;111:1848-54
   PubMed Web of Science ®Google Scholar
• Blum KA, Johnson JL, Niedzwiecki D, et al. Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. Leuk Lymphoma 2007;48:1313-9
   PubMed Web of Science ®Google Scholar
• Corazzelli G, Angrilli F, D'Arco A, et al. Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. Br J Haematol 2013;160:207-15
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Larson S, Trinkaus K, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011;118:5119-25
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Leonard JP, Younes A, et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009;146:171-9
   PubMed Web of Science ®Google Scholar
• Kaloyannidis P, Voutiadou G, Baltadakis I, et al. Outcomes of Hodgkin's lymphoma patients with relapse or progression following autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012;18:451-7
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Hamlin PA Jr, Perales MA, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 2013;31:456-60
   PubMed Web of Science ®Google Scholar
• Oki Y, Pro B, Fayad LE, et al. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 2008;112:831-6
   PubMed Web of Science ®Google Scholar
• Sarina B, Castagna L, Farina L, et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 2010;115:3671-7
   PubMed Web of Science ®Google Scholar
• Schnell R, Dietlein M, Staak JO, et al. Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol 2005;23:4669-78
   PubMed Web of Science ®Google Scholar
• Validire P, Ferme C, Brice P, et al. A multicenter study of gemcitabine-containing regimen in relapsed or refractory Hodgkin's lymphoma patients. Anticancer Drugs 2008;19:309-15
   PubMed Web of Science ®Google Scholar
• Venkatesh H, Di BN, Flynn TP, et al. Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma. Clin Lymphoma 2004;5:110-5
   PubMedGoogle Scholar
• Younes A, Romaguera J, Hagemeister F, et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003;98:310-4
   PubMed Web of Science ®Google Scholar
• Younes A, Oki Y, Bociek RG, et al. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2011;12:1222-8
   PubMed Web of Science ®Google Scholar
• Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol 2012;30:2197-203
   PubMed Web of Science ®Google Scholar
• Josting A, Schmitz N. Insights into 25 years of clinical trials of the GHSG: relapsed and refractory Hodgkin's disease. In: Diehl V, Josting A, eds. 25 years German Hodgkin Study Group. Munich: Urban & Vogel, 2004
   Google Scholar